https://www.borealis.vc/recentnews/ovation-and-precisionlife-identify-first-potential-genetic-biomarkers-to-predict-glp-1-efficacy-response/02.25.26/ba8f2cff-514b-4a9d-b78d-7ef1568a6107 2026-03-03 https://www.borealis.vc/recentnews/ankyra-therapeutics-presents-first-preclinical-data-on-ank-203/02.18.26/bc3921eb-6581-47fe-b357-63b34c863015 2026-03-03 https://www.borealis.vc/recentnews/compass-therapeutics-announces-key-leadership-appointments/01.05.26/9dd14ac2-7568-4eb3-a6a9-c1a9ee6251ca 2026-01-05 https://www.borealis.vc/recentnews/triveni-bio-named-to-fierce-biotech's-2025-fierce-15/09.22.25/c5afb554-abd7-451f-bd28-aa5c9eb0ff2d 2025-09-23 https://www.borealis.vc/recentnews/astra-therapeutics-raises-chf-7.75-million-in-seed-financing/07.24.25/9ca846f2-8cb5-4dea-a5ee-fda9a9a1ce4a 2025-07-24 https://www.borealis.vc/recentnews/triveni-bio-doses-first-healthy-volunteers-in-clinical-trial-for-triv-509/05.21.25/56c0215c-776e-402b-8390-852c82ab51c3 2025-05-28 https://www.borealis.vc/recentnews/compass'-tovecimig-(ctx-009)-meets-primary-endpoint-in-phase-2%2F3-study/04.01.25/a51e4854-1706-4e24-be4c-32467cd2fb40 2025-04-01 https://www.borealis.vc/recentnews/ankyra-announces-expansion-of-collaboration-with-j%26j-to-advance-il-12-anchored-drug-conjugate/01.10.25/921f6c2b-ebcf-4142-991a-67b392d412f4 2025-01-13 https://www.borealis.vc/recentnews/ovation.io-and-illumina-collaborate-to-advance-genomic-data-research/12.17.24/80f27c6c-bd14-4c94-b01c-0ca2ab89c265 2024-12-17 https://www.borealis.vc/recentnews/orbit-discovery-and-evergreen-theragnostics-expand-research-collaboration/12.03.24/e9b7da8c-a93d-4f6c-8ee8-4adf1126b610 2024-12-04 https://www.borealis.vc/recentnews/triveni-bio-raises-%24115m-series-b-to-expand-pipeline-addressing-i%26i-disorders/10.02.24/9c10f712-dfe7-4897-8066-ec081f3383ef 2024-10-02 https://www.borealis.vc/recentnews/ovation.io-completes-merger-with-pd-theranostics-creating-a-multiomic-data-company/09.05.24/b57891aa-5271-445f-a5a4-c255ec576c60 2024-09-11 https://www.borealis.vc/recentnews/compass-therapeutics-completes-patient-enrollment-in-companion-002/08.06.24/2b0f141e-3d6b-42f7-b42a-80acb18ae581 2024-08-06 https://www.borealis.vc/recentnews/triveni-bio-appoints-bhaskar-srivastava%2C-m.d.%2C-ph.d.%2C-as-chief-medical-officer/06.12.24/14ddc7d5-7efe-4ced-8ccc-474dadb67b84 2024-06-24 https://www.borealis.vc/recentnews/secarna-pharma-and-orbit-discovery-enter-collaboration-to-discover-peptide-conjugated-therapeutics/05.28.24/67b3c82a-fc7e-4ea1-ab3f-d259332e4089 2024-05-28 https://www.borealis.vc/recentnews/publication-in-nature-biomedical-engineering-highlights-improved-delivery-and-efficacy-using-evox-exosomes/05.20.24/f433eb4e-ad2b-4bec-ad1f-69049bbb0d71 2024-05-22 https://www.borealis.vc/recentnews/compass-therapeutics-receives-fda-fast-track-designation-for-ctx-009-in-combination-with-paclitaxel/04.25.24/8ed21945-9313-4cde-940c-b2b24f22befe 2024-04-26 https://www.borealis.vc/recentnews/compass-therapeutics-announces-first-patient-dosed-in-the-phase-1-study-of-ctx-8371/04.16.24/7bda8b56-757a-4c51-978e-7892a9ccb990 2024-04-18 https://www.borealis.vc/recentnews/ankyra-therapeutics-and-jenga-biosciences-announce-exclusive-license-agreement-for-jen-101/03.26.24/8f597eaf-59e3-4384-bebf-904994bcb5f6 2024-03-27 https://www.borealis.vc/recentnews/ankyra-therapeutics-announces-first-patient-dosed-in-phase-1-trial-evaluating-ank-101/03.05.24/9b58dbf3-f6d9-4e8f-aef6-a7cbfa4c82e4 2024-03-05 https://www.borealis.vc/recentnews/compass-therapeutics-announces-publication-of-preclinical-data-for-ctx-8371/02.28.24/5caa5427-aa49-4683-b777-522b50b9c645 2024-02-28 https://www.borealis.vc/recentnews/adimab-provides-year-end-update-on-2023-partnership-activities/01.08.24/880ba934-f2c8-456f-bc91-7f1cb3a4e8e4 2024-01-08 https://www.borealis.vc/recentnews/triveni-bio-welcomes-jeff-albers-and-allison-luo-to-its-board-of-directors/12.13.23/ded5b9e1-7fd7-446d-8b11-ccdc9cc166f4 2023-12-14 https://www.borealis.vc/recentnews/ankyra-therapeutics-announces-pre-clinical-research-published-in-jci-insight/12.12.23/c605bd83-ed4a-4a8a-9bc0-b6e42b3baba0 2023-12-14 https://www.borealis.vc/recentnews/ankyra-therapeutics-announces-clinical-supply-agreement-with-regeneron/11.13.23/6a05a2dc-fbf9-4e91-b1cc-acf2cd21c73b 2023-11-13 https://www.borealis.vc/recentnews/triveni-bio-launches-with-%2492-million-series-a-financing/10.26.23/3021b02e-5707-4f04-990d-223280788d72 2023-10-27 https://www.borealis.vc/recentnews/ankyra-therapeutics-receives-fda-ind-approval-to-advance-lead-program%2C-ank-101%2C-into-human-trials/10.24.23/7bc7cb1e-4014-474d-b68b-e1894d36a29e 2023-10-24 https://www.borealis.vc/recentnews/ankyra-therapeutics-announces-clinical-trial-collaboration-and-supply-agreement-with-merck/10.04.23/07f9438a-7892-43a2-9513-094125a1e402 2023-10-04 https://www.borealis.vc/recentnews/orbit-discovery-and-orano-med-collaborate-to-discover-radioligand-therapies-for-cancer/09.11.23/63542ac1-441d-43ee-a31e-75b7984150bc 2023-09-11 https://www.borealis.vc/recentnews/nature-communications-publication-highlights-evox-therapeutics'-advances/08.09.23/44399333-0ff9-4b30-98b6-62d3ad17fa52 2023-08-11 https://www.borealis.vc/recentnews/ankyra-therapeutics-appoints-robert-v.-tighe-as-chief-scientific-officer/08.07.23/39ab7aef-138f-4c16-9fc3-500d12afa227 2023-08-07 https://www.borealis.vc/recentnews/evox-enters-into-agreement-to-advance-exosome-delivered-aav-gene-therapy-for-heart-disease/08.04.23/e218eabe-bbaf-41b0-a1b3-16d4cd276539 2023-08-07 https://www.borealis.vc/recentnews/evox-therapeutics-acquires-exosome-aav-technology-and-ip-of-codiak-biosciences/06.20.23/bf218df7-36ce-48e1-8f53-f6ed6fb2f3df 2023-06-20 https://www.borealis.vc/recentnews/blue-rabbit-merges-with-wedgewood-pharmacy-to-deliver-veterinary-pharmacy-nationwide/06.14.23/ce78600e-4486-48e4-969c-b57a2c432047 2023-06-16 https://www.borealis.vc/recentnews/evox-therapeutics-granted-key-us-exosome-purification-patent/05.17.23/ef7a4d33-d0c3-481b-b82b-656660adb095 2023-05-19 https://www.borealis.vc/recentnews/orbit-discovery-and-evergreen-discovery-collaborate-to--discover-peptides/04.03.23/35094610-3e6d-48ce-adae-fbac2f94bbb1 2023-04-03 https://www.borealis.vc/recentnews/ankyra-therapeutics-announces-collaboration-with-johnson-%26-johnson/02.07.23/3d753d92-aea8-4258-aa4f-ece06412b0f6 2023-02-08 https://www.borealis.vc/recentnews/orbit-discovery-and-endevica-bio-enter-multi-target-collaboration/02.01.23/b14d1dec-aaec-4e29-88a8-43fab1c30af5 2023-02-01 https://www.borealis.vc/recentnews/compass-therapeutics-to-present-phase-2-data-of-ctx-009-with-paclitaxel-at-asco-gi-cancers-symposium/01.19.23/9bc6d0fe-f15e-44c8-862c-f076e95cb017 2023-01-20 https://www.borealis.vc/recentnews/wall-street-journal%3A-ovation-gathers-funding-to-extend-research-network/01.19.23/0854ccd5-e07e-4e75-9b80-5cb5fb1a544e 2023-01-19 https://www.borealis.vc/recentnews/adimab-provides-2022-update-on-clinical-pipeline/01.11.23/a37ad9ac-ee93-44f3-876d-261af0f7b92d 2023-01-11 https://www.borealis.vc/recentnews/adimab-provides-year-end-update-on-2022-partnership-activities/01.10.23/3a8f5a5d-2e59-47dc-8c5f-0d0a2ae6b0f4 2023-01-10 https://www.borealis.vc/recentnews/compass-therapeutics-announces-first-patient-dosed-in-phase-2-study-of-ctx-009/01.06.23/31467a9f-7e3b-467c-8f25-268041faadb8 2023-01-06 https://www.borealis.vc/recentnews/orbit-discovery-and-sanegenebio-collaborate-to-identify-targeting-peptides-for-rnai-drugs/01.05.23/11305f37-3f7f-4872-86dd-e03b5ce042b0 2023-01-05 https://www.borealis.vc/recentnews/compass-therapeutics-announces-first-patient-dosed-in-combination-trial-with-keytruda/12.01.22/57a0d97d-67a4-41da-acfa-fe01ae9dc8d7 2022-12-01 https://www.borealis.vc/recentnews/ovation-appoints-chief-revenue-officer-and-head-of-product-marketing/11.10.22/0e1bc75c-dc1f-4c38-a3cd-a9840c071b28 2022-11-14 https://www.borealis.vc/recentnews/compass-therapeutics-announces-%2480m-private-placement/11.02.22/5c70be49-fbff-4973-bb14-90cd7d5cf635 2022-11-02 https://www.borealis.vc/recentnews/ankyra-appoints-joseph-elassal-as-chief-medical-officer/10.17.22/9a235230-bacd-41cb-a6c2-3c8f2c5bd0aa 2022-10-17 https://www.borealis.vc/recentnews/compass-therapeutics-announces-clinical-collaboration-with-merck-to-evaluate-ctx-471--combination-/10.11.22/daf05bb3-2584-4494-b505-398305822045 2022-10-11 https://www.borealis.vc/recentnews/ovation-launches-ovation-research-network/07.12.22/5bf77af0-8658-41b9-843b-8cd0aaa971e4 2022-07-12 https://www.borealis.vc/recentnews/orbit-discovery-awarded-innovate-uk-grant-to-expand-platform/06.13.22/7daf5e58-22ab-4c2a-8aeb-615d93c15049 2022-06-14 https://www.borealis.vc/recentnews/ankyra-announces-collaboration-with-college-of-veterinary-medicine-at-university-of-illinois-/06.03.22/78f2722c-b281-4f52-a1eb-9bc3764bdf42 2022-06-03 https://www.borealis.vc/recentnews/compass-therapeutics-announces-reports-positive-interim-phase-2-data-of-ctx-009/05.04.22/0e3a0b53-e497-42ff-b785-13efbdc80870 2022-05-04 https://www.borealis.vc/recentnews/compass-announces-appointment-of-two-new-board-directors/04.26.22/89bb2fb7-0c7a-4691-be5f-fe671a845d39 2022-04-26 https://www.borealis.vc/recentnews/compass-therapeutics-presents-data-on-ctx-8371/04.08.22/43cb1646-3471-42fb-a393-2ebf54a3f311 2022-04-11 https://www.borealis.vc/recentnews/compass-therapeutics-to-present-on-ctx-8371-at-2022-aacr-annual-meeting/03.30.22/9245f227-b2b0-4e03-acc5-aaeced0e301e 2022-03-31 https://www.borealis.vc/recentnews/orbit-discovery-and-wuxi-apptec-sign-agreement-to-access-peptide-technologies/03.07.22/54385e16-b7c9-4549-9b89-fd35b7e42ae7 2022-03-09 https://www.borealis.vc/recentnews/adimab-announces-launch-of-four-new-proprietary-technologies/01.26.22/c6e73dc6-b441-4459-81cd-a79d751814d3 2022-01-26 https://www.borealis.vc/recentnews/compass-therapeutics-announces-fda-clearance-of-ind-application-for-phase-2-study-of-ctx-009/01.20.22/d4d6b67e-beb7-4010-a17c-53e9ac78d1d8 2022-03-09 https://www.borealis.vc/recentnews/adimab-provides-2021-update-on-clinical-pipeline/01.19.22/4d8c2f4a-39e0-4e94-b538-0bdcc7872d73 2022-01-21 https://www.borealis.vc/recentnews/antibody-legend-tillman-gerngross-introduces-latest-company/01.18.22/1c4275d6-620c-4852-b6de-24703a6af514 2022-01-18 https://www.borealis.vc/recentnews/amagma-therapeutics-announces-strategic-partnership-with-innovent-biologics/01.18.22/9a7e095e-4be3-4331-821c-e558dbb00086 2022-01-18 https://www.borealis.vc/recentnews/how-the-upper-valley-became-a-biotech-hub/01.12.22/3cae3885-35d9-432d-93d5-953c8a60f6b8 2022-01-18 https://www.borealis.vc/recentnews/adimab-provides-year-end-update-on-2021-partnership-activities/01.12.22/6aef9c1f-e84d-479a-8495-1c26adc185d6 2022-01-14 https://www.borealis.vc/recentnews/ankyra-therapeutics-announces-%2445m-series-b-and-appointment-of-chief-medical-officer/11.12.21/4e495460-4d63-4075-b386-c8dec1d57d28 2021-11-12 https://www.borealis.vc/recentnews/compass-announces-pricing-of-%24125m-public-offering-and-uplisting-to-nasdaq/11.01.21/4cf7fedb-ee0f-41f0-b75d-8765b71f6222 2021-11-02 https://www.borealis.vc/recentnews/compass-reports-the-advancement-of-ctx-009-to-phase-2a/11.01.21/12a3b866-e192-41df-b06b-052e30d03852 2021-11-01 https://www.borealis.vc/recentnews/landmark-paper-highlights-evox's-exosome-engineering-approach/10.07.21/896d8e7f-c08d-4d7e-944f-b77678ad885b 2021-11-01 https://www.borealis.vc/recentnews/teckro-launches-next-gen-clinical-trial-mobile-platform/09.29.21/5ed6c4db-d844-4f90-b1c6-c03ede709e84 2021-11-01 https://www.borealis.vc/recentnews/repligen-announces-agreement-to-acquire-avitide/09.16.21/52d78d08-2a5b-420d-8b52-d8048cf7b8e3 2021-11-01 https://www.borealis.vc/recentnews/orbit-discovery-announces-%247.6m-funding-to-accelerate-growth-in-peptide-discovery-business/07.20.21/3512fae7-b9f5-4756-ad00-9aab12ff539c 2021-11-01 https://www.borealis.vc/recentnews/t-cypher-bio-announces-the-appointment-of-thomas-lars-andresen-as-ceo/07.15.21/60055d52-eab4-486a-ae27-7a468469662c 2021-11-01 https://www.borealis.vc/recentnews/evox-wins-best-emerging-biotech-at-the-obn-awards-ceremony/06.14.21/dcc7855c-481c-4dd6-a5bc-45811a632043 2021-11-01 https://www.borealis.vc/recentnews/compass-therapeutics-to-acquire-trigr-therapeutics/05.13.21/70d2f69a-43e0-4eb6-a01a-91846d0e5f3d 2021-05-13 https://www.borealis.vc/recentnews/compass-therapeutics-reports-2020-results-and-partial-response/03.05.21/66902083-bfa0-4f23-a6a9-169d81e45881 2021-03-05 https://www.borealis.vc/recentnews/t-cypher-bio-separates-from-orbit-discovery-to-pursue-tcr-therapeutics/02.25.21/a51952e6-5a79-43f9-99ae-4ee3dc64430d 2021-03-05 https://www.borealis.vc/recentnews/evox-therapeutics-completes-%2495.4-million-series-c-financing/02.18.21/a3b54e27-1aeb-4265-b7c1-94b9b5905c25 2021-02-18 https://www.borealis.vc/recentnews/adimab-provides-year-end-update-on-2020-partnering-activities/02.11.21/080b2f58-fe36-4476-81d1-af9057d14c86 2021-02-18 https://www.borealis.vc/recentnews/adimab-provides-2020-update-on-clinical-pipeline/02.09.21/660a0a1a-edc9-48de-885c-4b46ae1f9370 2021-02-18 https://www.borealis.vc/recentnews/ovation-raises-%2421.5m-to-transform-the-future-of-lab-software/12.16.20/54bdfd5e-2e74-4345-9c7d-b75178a894af 2020-12-16 https://www.borealis.vc/recentnews/ovation-launches-pooled-testing-to-bolster-covid-19-offering/08.20.20/9f7b2900-6b9e-4bd1-b8e7-c6722be55cac 2020-08-20 https://www.borealis.vc/recentnews/teckro-looks-to-future-on-5th-anniversary%3A-expands-leadership-team-to-accelerate-growth/07.21.20/8405d36c-c9f2-4c7a-a95e-42091f49f5ca 2020-07-22 https://www.borealis.vc/recentnews/adimab-spins-out-adagio-therapeutics-to-develop-broadly-protective-coronavirus-antibodies/07.16.20/54787b42-ddf4-4935-8b96-0aa5e2bfc2ff 2020-07-16 https://www.borealis.vc/recentnews/compass-therapeutics-completes-reverse-merger-and-closes-%2460-million-private-placement/06.23.20/e02a3c81-b03f-49d6-9edd-013d17e1c762 2020-06-24 https://www.borealis.vc/recentnews/evox-announces-multi-target-collaboration-with-lilly/06.09.20/b101bae3-cf26-4916-9b83-c679cb1800ae 2020-06-09 https://www.borealis.vc/recentnews/evox-therapeutics-appoints-paul-carter-as-non-executive-chairman/05.14.20/d55f816d-1c89-4d72-99f2-c820fb156674 2020-05-14 https://www.borealis.vc/recentnews/compass-therapeutics'-i-o-prospect-clears-solid-tumors-in-mice/04.04.20/50ad2c82-f1ad-4db3-bf73-90aa7b6f6cea 2020-04-04 https://www.borealis.vc/recentnews/evox-and-takeda-sign-multi-target-rare-disease-collaboration/03.26.20/a639b9a7-c15a-4e8d-9508-a83981135df5 2020-03-26 https://www.borealis.vc/recentnews/ovation.io-launches-effort-to-double-covid-19-testing-capacity/03.20.20/34b92de2-6d85-431b-bc10-c4a58263d2b4 2020-03-20 https://www.borealis.vc/recentnews/avitide-announces-allergan-partnership-expansion/01.13.20/735aaa2f-9a94-4a59-9124-6822600a8b16 2020-01-13 https://www.borealis.vc/recentnews/adimab-provides-update-on-2019-partnership-activities/01.10.20/e5d845f5-3958-41f3-87fb-80201559408d 2020-01-13 https://www.borealis.vc/recentnews/avitide-and-gemini-therapeutics-enter-into-exclusive-license-agreement/12.09.19/c3196493-6ba9-40ed-98ae-8cea36fd1a43 2019-12-10 https://www.borealis.vc/recentnews/glaukos-completes-acquisition-of-avedro%2C-inc./11.21.19/2898e62f-716c-486c-b619-f229b26f790f 2019-12-10 https://www.borealis.vc/recentnews/compass-therapeutics-appoints-scientific-advisory-board/10.22.19/fbfc9e8d-cf17-49eb-a750-983fdbc81a00 2019-12-10 https://www.borealis.vc/recentnews/mario-polywka-joins-orbit-discovery%E2%80%99s-board-of-directors/08.30.19/0db26509-862d-4ae6-80b4-eaf5fbfcc4c8 2019-12-16 https://www.borealis.vc/recentnews/glaukos-and-avedro-announce-definitive-acquisition-agreement/08.07.19/92f69177-3c94-4467-a16c-611cc28b9552 2019-08-27 https://www.borealis.vc/recentnews/evox-therapeutics-granted-key-exosome-patents/08.07.19/ca2ae3ea-81bb-4a36-85eb-1ad592b9fdd4 2019-08-27 https://www.borealis.vc/recentnews/compass-therapeutics-announces-first-patient-dosed-in-phase-1-trial-of-ctx-471/07.08.19/090e9874-b71b-43ea-b121-3c6681e12cbd 2019-08-27 https://www.borealis.vc/recentnews/teckro-ceo-gary-hughes%E2%80%99-appetite-for-disruption/07.05.19/eb35be56-9002-4765-80a7-405e52e64cbb 2019-08-27 https://www.borealis.vc/recentnews/covetrus-takes-home-nevy-award-for-healthcare-it-exit-of-the-year/05.09.19/ccae8b3a-34e9-46dd-9381-8c87e0f590d4 2019-08-27 https://www.borealis.vc/recentnews/adimab-broadens-r%26d-deals-with-novartis%2C-regeneron%2C-takeda/05.08.19/e1fc72a9-dc43-4a0e-9091-8379c28af6b2 2019-08-27 https://www.borealis.vc/recentnews/ovation.io-secures-%245-million-series-a-funding/03.14.19/292b4b47-50b1-443b-bd0d-5f4a525686a2 2019-08-27 https://www.borealis.vc/recentnews/teckro-raises-%2425-million-series-c-financing/02.14.19/2a943a7e-5aac-4f50-918b-be6976373ff8 2019-08-27 https://www.borealis.vc/recentnews/covetrus-celebrates-launch-as-newly-formed-public-company/02.08.19/ca3ee34f-ffde-4c51-aa2c-af06ea1badf3 2019-08-27 https://www.borealis.vc/recentnews/avedro-launches-initial-public-offering/02.04.19/32c28220-701a-471b-897d-08ccd365180e 2019-08-27 https://www.borealis.vc/recentnews/adimab-provides-2018-update-on-clinical-pipeline/01.09.19/45a800ae-bb5f-4ddb-b552-706ff9f07b42 2019-08-27 https://www.borealis.vc/recentnews/fiercebiotech-names-compass-therapeutics-a-2018-%E2%80%9Cfierce-15%E2%80%9D-biotech-company/10.02.18/f45c4e04-1b40-4f59-ba03-ea2851221ca1 2019-08-27 https://www.borealis.vc/recentnews/vets-first-choice-wins-approval-to-build-new-headquarters-in-downtown-portland/09.26.18/c9afc017-46b7-4ef4-a70f-0f47be828a56 2019-08-27 https://www.borealis.vc/recentnews/evox-therapeutics-completes-%C2%A335-million-series-b-financing/09.01.18/c61ee103-6c78-41e7-829f-b8cb26c7f89d 2019-08-27 https://www.borealis.vc/recentnews/compass-therapeutics-completes-%24132-million-series-a-financing/07.12.18/1e8aee9e-946b-475e-a657-1bfaf761f2b7 2019-08-27 https://www.borealis.vc/recentnews/orbit-discovery-closes-%C2%A36.9-million-series-a-financing/05.23.18/0decad24-bfb2-4e44-8ba0-231cf42e9931 2019-08-27 https://www.borealis.vc/recentnews/vets-first-choice-to-merge-with-henry-schein-animal-health/04.23.18/60609a8f-dbf6-470b-a0a1-c20237e894de 2019-08-27 https://www.borealis.vc/recentnews/adimab-announces-antibody-discovery-collaboration-with-boehringer-ingelheim/01.10.18/b687ddea-e38d-44e5-b880-6c2394d59170 2019-08-27 https://www.borealis.vc/recentnews/adimab-provides-year-end-update-on-2017-partnership-activities/01.08.18/f08eb9b0-ae49-4b53-bbd4-0e403cef9c73 2019-08-27